



## US institution Platinum Partners LLC invests in Starpharma

**Melbourne, Australia. Tuesday 21<sup>st</sup> August 2007.** Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced a AU\$2.8 million investment by Platinum Partners LLC, a large US-based institution. Following from this significant investment, a key existing institutional shareholder has agreed to invest a further AU\$1.0 million on the same terms, bringing the total placement to AU\$3.8 million.

Platinum Partners LLC, has agreed to acquire 8,768,389 ordinary shares in a private placement priced at AU\$0.32 per share. Platinum will also be issued 5,261,033 options with an exercise price of AU\$0.44. San Francisco-based Merriman Curhan Ford and Co, served as corporate advisors to the placement.

A further 3,112,778 shares and 1,867,667 options will be issued to the participating existing institutional shareholder.

The proceeds of the placement will principally be used to support the further development and commercialisation of Starpharma's dendrimer programs, in particular drug delivery, its PrioFect™ siRNA delivery technology and the condom coating line-extension of VivaGel™.

"We are pleased to be making an investment in Starpharma Holdings, our first investment in an Australian biotech company. We consider Starpharma's dendrimer portfolio, including VivaGel™ and their siRNA delivery technology, to be very exciting and valuable assets." said Dr Michael Goldberg of Platinum Partners.

"We also consider the opportunity for dendrimers in drug delivery to have significant potential," Dr Goldberg added. Platinum Partners LLC is a New York-based investment fund which invests globally.

Dr Jackie Fairley, CEO of Starpharma added: "We are delighted to have a fund of Platinum's size and calibre on Starpharma's register. We consider this investment and the additional investment from an existing Australian institution to be recognition of the significant commercial opportunities for our products globally and an increasing awareness of Starpharma's potential amongst US investors."

"This investment strengthens our capital structure and opens up further opportunities for us in the US market." Following this investment Starpharma's US institutional holding is increased to 13% and total US shareholding will be approaching 25%.

---

### About Starpharma:

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel™ (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of HIV and genital herpes.



In the pharmaceutical field Starpharma has additional specific programs in the areas of Drug Delivery and ADME Engineering™ (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).

More broadly the company is exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

SPL has a comprehensive IP portfolio that comprises more than 180 patents/applications issued and pending across 32 patent families - a unique level of IP concentration among nanotechnology companies.

**Dendrimers:** A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

**Microbicides:** A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function.

**American Depositary Receipts (ADRs):** Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depository bank.

**Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

**For further information:**

<b>Media</b>	<b>Starpharma</b> <a href="http://www.starpharma.com">www.starpharma.com</a>	
<b>Rebecca Wilson</b> <b>Buchan Consulting</b> Tel: +61 2 9237 2800 Mob: +61 417 382 391 rwilson@bcg.com.au	<b>Dr Jackie Fairley</b>  Chief Executive Officer +61 3 8532 2704	<b>Ben Rogers</b>  Company Secretary +61 3 8532 2702 ben.rogers@starpharma.com